Skip to main content
01274 442076
Cost of ARRS Roles: What PCNs Need to Know Before They Decide
22nd May 2026
- What are the hidden costs of ARRS roles?
- How should PCNs measure the return on investment from ARRS?
- How does procurement influence cost and risk?
Understanding the cost of ARRS roles is one of the most important financial decisions a PCN makes. On paper, roles like Clinical Pharmacists and Pharmacy Technicians are reimbursed through the additional roles reimbursement scheme. In practice, the true cost of ARRS roles depends on how you recruit, manage, supervise, and deploy them.
For a full list of ARRS roles and eligibility criteria, see our ARRS support page for roles, funding, and eligibility.
If you are weighing up total spend, the return on investment, and the hidden costs of ARRS roles that sit outside the reimbursement cap, this guide will help you compare and decide with confidence.
What is the cost of ARRS roles?
The true cost of ARRS roles goes beyond that once supervision, deployment, and infrastructure are factored in. Understanding this gap helps PCNs plan effectively and avoid unexpected budget pressures.
Key takeaways
- Total cost: Extends beyond reimbursement to include supervision, training, and infrastructure.
- Hidden Costs: Recruitment associated costs, operating model leakage, and governance time, and clinical supervision often sit outside the cap.
- Return on investment: ROI is usually measured in capacity release, quality improvements, and performance against network priorities.
- Procurement Models: Your procurement model, such as an arrs managed service, has a direct impact on cost certainty and delivery consistency.
Anything above the arrs reimbursement cap must be funded. That is where arrs workforce cost can quickly rise if expectations are not aligned to budget.
What are the hidden costs of ARRS roles?
ARRS roles are often described as “fully funded,” but they are not always fully cost-neutral. Here are the common hidden costs that influence your real spend.
1. Supervision and governance time
Clinical Pharmacists and Pharmacy Technicians require structured supervision. That time often comes from senior pharmacists or GP supervisors and has an opportunity cost.
2. Time to productivity
New ARRS staff do not operate at full capacity on day one. Training pathways and local induction can take months, during which time productivity may be lower than expected. This is a significant and often overlooked element of total workforce cost that is rarely factored into initial planning.
3. Recruitment gaps
If you recruit directly and experience delays, your allocation may sit unused while practices and PCNs still face workload pressure. Staying within the arrs reimbursement cap while managing these gaps requires careful planning.
4. Infrastructure and systems
Laptops, smartcards, estates space, and admin support all require setup and management.
5. Operating model leakage
Variation across practices in referral pathways, appointment books, and admin processes can reduce utilisation and ROI. You pay the cost, but don’t get the outputs.
How should PCNs measure the return on investment from ARRS?
ARRS return on investment is rarely about generating income. It is about measurable system benefit. Strong returns are usually seen in three areas:
- Capacity release: GP appointments freed from medicines queries, Structured Medication Reviews delivered at scale, and a streamlined repeat prescribing workflow.
- Quality and safety improvement: High-risk medicines monitoring compliance, medicines optimisation in long-term conditions, and reduced prescribing errors.
- Performance against network priorities: ARRS roles can directly support QOF and local incentive delivery.
The key is measurement. If outputs are not tracked, ROI becomes anecdotal rather than strategic decision-making.
How does procurement influence cost and risk?
The decision to recruit directly or commission an arrs managed service has a major impact on cost and risk. The cost of clinical pharmacist arrs roles, for example, varies significantly depending on whether supervision, cover, and governance are bundled into a managed model or absorbed locally. How you structure the model also determines how much of your arrs funding allocation translates into genuine clinical output. Key differences are worth comparing before you commit.
| Factor | Direct Employment | Managed Service |
| Recruitment | PCN responsibility | Provider manages |
| Supervision | Internal | Included |
| Speed to deploy | Slower | Faster |
| Cost certainty | Variable | More predictable |
| Governance b | Carried locally | Bundled in |
Key procurement levers that affect total cost include:
- Who covers supervision (provider vs PCN time)
- Reporting cadence, frequency and KPI definitions
- Deployment model across practices
Expert insight from Adeem Azhar, qualified Clinical Pharmacist and CEO
ARRS funding is a huge opportunity for PCNs, but funding alone does not guarantee impact. The model you choose determines whether you gain real capacity and long-term value, or simply add complexity.
Adeem Azhar, MPharm, IPres
Co-Founder and Chief Executive Officer – Core Prescribing Solutions
Qualified Clinical Pharmacist
When you evaluate costs properly and factor in hidden costs and procurement decisions, you move from simply filling a funded role to building a smarter workforce model that delivers measurable value.
Frequently asked questions
Looking for support with ARRS workforce planning?
If your PCN wants a structured ARRS delivery model that improves safety, governance, and measurable outcomes, our dedicated ARRS support service provides full workforce design and implementation support.
